27th Jul 2023 21:08
AstraZeneca PLC - Cambridge-based pharmaceutical firm - Says Soliris approved in EU for treatment of refractory generalised myasthenia gravis in those aged between six and 17. "This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU," AstraZeneca says. Myasthenia gravis is a disease that causes muscle weakness. Separately, Astra says Enhertu shows meaningful progression-free survival and overall survival in some cancer sufferers. The measures are two secondary endpoints of a phase II trial. Enhertu is being jointly-developed by Astra and Daiichi Sankyo Co Ltd.
Current stock price: 10,802.00 pence
12-month change: down 0.6%
By Eric Cunha, Alliance News news editor
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca